U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
102902102902Post Market (Brioâ„¢ System) Deep Brain Stimulation (DBS) PD StudyWithdrawnNo Results AvailableParkinson Diseasehttps://ClinicalTrials.gov/show/NCT01218919
102903102903Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in AsiaCompletedNo Results AvailableDengue Fever|Feverhttps://ClinicalTrials.gov/show/NCT01218906
102904102904Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine ProphylaxisCompletedNo Results AvailablePlasmodium Falciparum MalariaDrug: Chloroquine prophylaxis|Biological: Immunization|Biological: Plasmodium falciparum challenge|Drug: Malarone treatmenthttps://ClinicalTrials.gov/show/NCT01218893
102905102905Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic CancerRecruitingNo Results AvailablePancreatic CancerDrug: M2ES 7.5mg|Drug: M2ES 15mg|Drug: M2ES 30mg|Drug: M2ES 45mghttps://ClinicalTrials.gov/show/NCT01218880
102906102906CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic CancerRecruitingNo Results AvailableMetastatic Cancer|Metastatic Melanoma|Renal CancerBiological: Anti-VEGFR2 CAR CD8 plus PBL|Drug: Cyclophosphamide|Biological: Aldesleukin|Drug: Fludarabinehttps://ClinicalTrials.gov/show/NCT01218867
102907102907A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue BiopsyRecruitingNo Results AvailableLung Neoplasms|Liver Neoplasms|Kidney Neoplasms|CancerDevice: Needle angle measurementhttps://ClinicalTrials.gov/show/NCT01218854
102908102908Pure Fish Oil Parenteral Lipid Emulsion in Patients With Gastrointestinal CancerCompletedNo Results AvailableSurgeryDietary Supplement: Fish oil lipid emulsion|Dietary Supplement: MCT/LCThttps://ClinicalTrials.gov/show/NCT01218841
102909102909Prevention of Contrast Renal Injury With Different Hydration StrategiesCompletedNo Results AvailableContrast Medium-induced NephropathyOther: LVEDP -Based hydration strategy|Other: Standard hydrationhttps://ClinicalTrials.gov/show/NCT01218828
102910102910Complete Infarct Related Artery RevascularizationTerminatedNo Results AvailableMyocardial Infarction|Coronary Artery DiseaseProcedure: IRA stenting in culprit lesion only|Procedure: IRA stentinghttps://ClinicalTrials.gov/show/NCT01218815
102911102911Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular RisksCompletedNo Results AvailableHIV Infections|Heart DiseaseDrug: Rosuvastatin 10 mg. daily for 96 weeks|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01218802
102912102912Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light PerceptionRecruitingNo Results AvailableNon 24 Hour Sleep Wake DisorderDrug: tasimelteonhttps://ClinicalTrials.gov/show/NCT01218789
102913102913International Survey of Acute Coronary Syndromes in Transitional CountriesRecruitingNo Results AvailableAcute Coronary Syndrome|Unstable Angina Pectoris|Myocardial Infarction|Coronary Diseasehttps://ClinicalTrials.gov/show/NCT01218776
102914102914CANadian Clinical Evaluation of SpiderFlash Arrhythmia DETECTion in SpiderFlashâ„¢ DeviceRecruitingNo Results AvailableArrhythmias, Cardiachttps://ClinicalTrials.gov/show/NCT01218763
102915102915Triple Therapy for Diffuse Diabetic Macular EdemaRecruitingNo Results AvailableDiffuse Diabetic Macular EdemaProcedure: Triple therapy for diffuse diabetic macular edemahttps://ClinicalTrials.gov/show/NCT01218750
102916102916Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/InflammationCompletedNo Results AvailableInfection and Inflammation After Refractive Surgery (Lasik).Drug: 0.3% gatifloxacin and 1.0% prednisolone acetate association|Drug: isolated 0.3% gatifloxacin and 1.0% prednisolone acetatehttps://ClinicalTrials.gov/show/NCT01218737
102917102917Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human VolCompletedNo Results AvailableHealthyDrug: Losartan Potassium and Hydrochlorothiazide Tabletshttps://ClinicalTrials.gov/show/NCT01218724
102918102918Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human VolCompletedNo Results AvailableHealthyDrug: Losartan Potassium and Hydrochlorothiazide Tabletshttps://ClinicalTrials.gov/show/NCT01218711
102919102919Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fed ConditionCompletedNo Results AvailableHealthyDrug: Losartan Potassium Tabletshttps://ClinicalTrials.gov/show/NCT01218698
102920102920Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and PregnantsCompletedNo Results AvailableImmunocompromised Patients|Safety of Pandemic Influenza A (H1N1)Vaccine|Immunogenicity of Pandemic Influenza A (H1N1)VaccineBiological: Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUShttps://ClinicalTrials.gov/show/NCT01218685
102921102921A Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPSâ„¢ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic HyperplasiaActive, not recruitingNo Results AvailableBenign Prostatic HyperplasiaDevice: GreenLight XPS vs. TURPhttps://ClinicalTrials.gov/show/NCT01218672
102922102922Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry DiseaseCompletedNo Results AvailableFabry DiseaseDrug: migalastat hydrochloride|Biological: agalsidasehttps://ClinicalTrials.gov/show/NCT01218659
102923102923Study of Quadrivalent Influenza Vaccine Among AdultsCompletedHas ResultsInfluenzaBiological: Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative|Biological: Investigational Trivalent Inactivated Influenza Vaccine, No Preservative|Biological: Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|Biological: Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservativehttps://ClinicalTrials.gov/show/NCT01218646
102901102901Pharmacokinetic Study of Primaquine and Chloroquine in Healthy SubjectsCompletedNo Results AvailableVivax MalariaDrug: A|Drug: Bhttps://ClinicalTrials.gov/show/NCT01218932
102924102924Dose-response Study of Exendin-9,39 on Glucose MetabolismCompletedNo Results AvailablePancreatic Effects of 9,39-Exendin and 9,36-GLP-1Drug: saline infusion|Drug: GLP-1-9,36 infusion|Drug: Exendin-9,39 at low dose|Drug: Exendin-9,39 at high dosehttps://ClinicalTrials.gov/show/NCT01218633
102925102925Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid TumorsCompletedNo Results AvailableAdult Solid NeoplasmDrug: Gamma-Secretase Inhibitor RO4929097|Drug: Ketoconazole|Drug: Rifampin|Drug: Midazolam Hydrochloride|Drug: Omeprazole|Drug: Tolbutamide|Drug: Dextromethorphan Hydrobromide|Other: Pharmacological Study|Other: Laboratory Biomarker Analysishttps://ClinicalTrials.gov/show/NCT01218620
102926102926Bosentan for Mild Pulmonary Vascular Disease in Asd Patients.CompletedNo Results AvailableHeart Septal Defects, AtrialDrug: Bosentan|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01218607
102927102927Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung CancerActive, not recruitingHas ResultsNon-small Cell Lung CancerDrug: Endostatinhttps://ClinicalTrials.gov/show/NCT01218594
102928102928Aromatase Inhibitors or GnRH-a for Uterine AdenomyosisCompletedNo Results Availablethe Efficacy of Aromatase Inhibitor vs. Gonadotrpins Releasing Hormone Agonists in Treating Premenopausal Women With Uterine AdenomyosisDrug: received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)https://ClinicalTrials.gov/show/NCT01218581
102929102929Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized TrialCompletedNo Results AvailableHepatic EncephalopathyDrug: Rifaximin plus lactulose|Drug: Lactulosehttps://ClinicalTrials.gov/show/NCT01218568
102930102930Study of Everolimus (RAD001) in Combination With LenalidomideRecruitingNo Results AvailableSolid Organ Malignancies|Adenoidcystic Carcinoma|Neuroendocrine TumorsDrug: Lenalidomide|Drug: Everolimushttps://ClinicalTrials.gov/show/NCT01218555

* Görseller ve İçerik tekif hakkına sahip olabilir